SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers

Background: Patients with epithelial ovarian cancer (EOC) receiving neoadjuvant platinum-based chemotherapy (NACT) who remain ineligible for complete interval cytoreductive surgery (ICS) due to poor chemosensitivity (CA-125 KELIM™ score <1.0) have a poor prognosis (~20% 5-year survival). A weekly do...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Claire Chator, Nozomu Yanaihara, Sylvie Chabaud, Gabriella Maria Parma, Alexandra L. Dima, Andrew Clamp, Gwenaël Ferron, Judith R. Kroep, Alexandra Leary, David Cibula, Frederic Fiteni, Ilan Bruchim, Hassan Serrier, Susannah Carroll, Anne-Sophie Belmont, Julien Peron, Benoit You
Formato:	Artigo
Idioma:	Inglês
Publicado em:	SAGE Publishing 2025-12-01
coleção:	Therapeutic Advances in Medical Oncology
Acesso em linha:	https://doi.org/10.1177/17588359251396777
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!